Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs
Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs
复制标题
DOI：
10.1093/cid/cit301
复制
发表时间：
2013-08-15
影响因子：
11.8
通讯作者：
Dalgard, Olav
中科院分区：
文献类型：
--
作者：
Grady, Bart P.;Schinkel, Janke;Dalgard, Olav
在发达国家，大多数丙型肝炎病毒（HCV）感染新病例与注射吸毒有关。然而，对注射吸毒者的治疗存在争议，因为治疗成功后可能会出现新的感染。在持续的病毒学反应后再次感染已经有报道，但是风险如此之大以至于应该对这一庞大的HCV人群停止治疗吗？初步证据表明，再感染发生率较低，但迄今为止的研究受样本量小和再感染病例少的限制。在这篇综述中，我们评估了治疗后丙型肝炎再感染的PWID的研究数据，以合理估计再感染的出现频率，并试图描述那些最危险的人群。观察到治疗后丙型肝炎再感染的自发清除提示了对持续感染的部分保护性免疫。
Most new cases of hepatitis C virus (HCV) infections in the developed world are associated with injection drug use. However, treatment for people who inject drugs (PWID) is controversial, as successful treatment risks being followed by new infection. Reinfection after sustained virologic response has been reported, but is the risk so great that treatment should be withheld from this large HCV population? Preliminary evidence suggests that the reinfection incidence is low, but studies to date have been limited by small sample size and few cases of reinfection. In this review, we assess data from studies among PWID of HCV reinfection following treatment to give a reasonable estimate on how frequently reinfection appears and try to characterize those most at risk, The observation that spontaneous clearance of HCV reinfection following treatment occurs is suggestive of a partial protective immunity against persistent infection.